Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
January 1, 2026, to August 16, 2026. Candidates will be evaluated continuously until multiple positions are filled. These are one-year, benefits-eligible positions that are potentially renewable
-
to develop novel immune therapeutic strategies for hard-to-treat triple negative breast cancers (TNBC). Based in the Cancer Bioinformatics Group (Professor Anita Grigoriadis), the postholder will contribute
-
. Areas of specialization may encompass a wide range of study, including but not limited to bioinformatics, computational genomics, systems biology, computational drug discovery, biomedical/health
-
University Hospital, Duke Regional Hospital, Duke Raleigh Hospital, Duke Health Integrated Practice, Duke Primary Care, Duke Home Care and Hospice, Duke Health and Wellness, and multiple affiliations. Summary
-
/Seurat, count models, batch correction, differential analyses). Strong grounding in statistics (GLMs, hierarchical/Bayesian modeling, multiple testing) and experimental-design principles. Bioinformatics
-
& Bioinformatics, is seeking candidates for a postdoctoral research fellow position. This is primarily for an NIH-funded project developing multimodal variational autoencoder models and probabilistic trajectory
-
University of Colorado offers an excellent benefits package including: Medical: Multiple plan options Dental: Multiple plan options Additional Insurance: Disability, Life, Vision Retirement 401(a) Plan
-
clinical translation. Our work is supported by multiple NIH grants, including funding from NIAMS, the NIH AMP-AIM Team Science Leadership Scholars Program, and the Office of Research on Women’s Health, as
-
Postdoctoral Fellow Positions in Microbiome, Immunology, and Bioinformatics - (250000Q8) Postdoctoral Positions in Microbiome, Immunology, and Bioinformatics Opening in Fall 2025, the Translational
-
Job Description Overview: Our lab uses tools from molecular biology, immunology, and bioinformatics to understand the interplay between pathogens, the mucosa, and pharmacological interventions